FactClazakizumab is a humanized monoclonal antibody, discovered by Alder, which binds to and inhibits IL-6. IL-6 is an important driver of the inflammatory response and is implicated in the transition from acute to chronic inflammation.
FactGlobal sales of rheumatoid arthritis therapies were more than US$12 billion in 2012 and will grow to US$15 billion by 2016.
FactRheumatoid arthritis is a chronic inflammatory disorder that principally attacks joints. Approximately 2.4 million patients, predominantly women, suffer from RA in the United States.
FactALD403 is a monoclonal antibody, discovered by Alder, which targets CGRP for prevention of migraine. CGRP is a small protein that is involved in the transmission and heightened sensitivity to pain experienced in migraine.
FactAccording to the American Migraine Foundation, migraine is three times more common in women than men and migraine affects 30% of women over a lifetime.
FactAccording to a 2012 report by the U.S. Agency for Healthcare Research and Quality, headaches accounted for 2.1 million visits to the emergency room annually.
FactFor the 11 million U.S. migraine patients who are candidates for migraine prevention, there are few therapeutic options to manage their disease.
FactThe Migraine Research Foundation estimates U.S. employers lose more than US$13 billion each year as a result of 113 million lost workdays due to migraine.
FactMigraine is a significant cause of disability, generally affecting individuals between the ages of 20 and 50, their prime working years.
FactApproximately 36 million Americans suffer from migraines, but only 20 million migraine sufferers have been clinically diagnosed.